Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours

@article{Cianfrocca2006Phase1T,
  title={Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours},
  author={Mary E. Cianfrocca and Kathryn A. Kimmel and Jose Gallo and Tanusha Cardoso and Matthew M Brown and Gary H Hudes and Nancy Lewis and L Wagner Weiner and Gilbert N. Lam and Steven C. Brown and David E. Shaw and Andrew P. Mazar and Roger B. Cohen},
  journal={British Journal of Cancer},
  year={2006},
  volume={94},
  pages={1621 - 1626}
}
To evaluate the toxicity, pharmacological and biological properties of ATN-161, a five –amino-acid peptide derived from the synergy region of fibronectin, adult patients with advanced solid tumours were enrolled in eight sequential dose cohorts (0.1–16 mg kg−1), receiving ATN-161 administered as a 10-min infusion thrice weekly. Pharmacokinetic sampling of blood and urine over 7 h was performed on Day 1. Twenty-six patients received from 1 to 14 4-week cycles of treatment. The total number of… CONTINUE READING
53 Citations
41 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 53 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

ATN-161 (Ac-PHSCN-NH2) has potent anti-angiogenic activity through multiple mechanisms of action and localizes to newly formed blood vessels in vivo

  • F Donate, X Guan, JA Callahan, AP Mazar, GC Parry
  • Proc Am Assoc Cancer Res
  • 2003
2 Excerpts

Similar Papers

Loading similar papers…